PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Clinical trials for PULMONARY ALVEOLAR PROTEINOSIS (PAP) explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ALVEOLAR PROTEINOSIS (PAP) trials appear
Sign up with your email to follow new studies for PULMONARY ALVEOLAR PROTEINOSIS (PAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug shows promise for rare immune disorders
Disease control CompletedThis early-phase study tested the safety of rituximab, a drug that targets faulty white blood cells, in 7 adults with rare immune diseases like pulmonary alveolar proteinosis and severe candidiasis. Participants received several doses over 6 months and were monitored for 18 month…
Matched conditions: PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Scientists investigate why rare lung disease develops in children
Knowledge-focused CompletedThis study looked at 20 children with a rare lung condition called pulmonary alveolar proteinosis (PAP) caused by changes in the MARS gene. Researchers wanted to understand if the lung cleaning cells (macrophages) are not working properly. They grew these cells in a lab from bloo…
Matched conditions: PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC